OVV-01
AXP000132.1 · Oncolytic virus
- Platform
- vesicular stomatitis virus (recombinant, NY-ESO-1-armed)
Names
| Name | Type | Source |
|---|---|---|
| OVV-01 | preferred name, code | curator, ctgov |
| C045 ambiguous | code | ctgov |
| oncolytic virus (OVV-01) injection | synonym | ctgov |
Virus
- Role
- Oncolytic
- Family
- Rhabdoviridae
- Virus
- vesicular stomatitis Indiana virus (NCBI Taxonomy 11277)
- Strain
- Indiana, recombinant
- Replication
- replicating
- Modifications
- recombinant VSV engineered for selective replication in tumour cells (details not published)
- Transgenes
- NY-ESO-1 (CTAG1B)
- Route
- intratumoral
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (5)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07650838 | OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS) | Not yet recruiting | Phase 2 | 2026-08-01 | 2027-12-31 | 40 | Soft Tissue Sarcoma (STS) |
| NCT07650825 | OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors | Not yet recruiting | Phase 1 | 2026-08-01 | 2027-01-31 | 30 | Advanced Solid Tumors |
| NCT07648472 | A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours. | Recruiting | Phase 1 | 2026-04-21 | 2027-04-20 | 18 | Advanced Solid Tumors |
| NCT05271279 | A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors | Terminated | Early phase 1 | 2021-12-24 | 2022-08-29 | 2 | Advanced Solid Tumor; Relapsed/Refractory Lymphoma |
| NCT04787003 | Oncolytic Virus (OVV-01) Injection in the Treatment of Patients With Advanced Solid Tumors | Unknown | Phase 1 | 2021-02-16 | 2023-10-01 | 50 | Neoplasms |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40480657 | Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors. | Journal for immunotherapy of cancer | 2025 | cited by trial NCT04787003 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40873562 | Mechanism of action of over-expressing NY-ESO-1 in vesicular stomatitis virus and its combination therapy with NY-ESO-1 TCR-T. | Frontiers in immunology | 2025 | name in abstract: OVV-01 |
Notes
Genetically engineered oncolytic VSV expressing the tumour antigen NY-ESO-1; first-in-human phase 1 NCT04787003 dosed 18 patients intratumorally (Hua et al., J Immunother Cancer 2025, PMID 40480657). Trial code C045. Commercial developer not named in the registration or the paper abstract; left empty.
How to cite
OVV-01 (AXP000132.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000132.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.